Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 2/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.51 |
| ▸ | RHEB | Q15382 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | CBFB | Q13951 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3871577 | 0.86 | EGLN1 (0.55) | PIN1HRH4HRH3EGLN1RHEB | |
| SCHEMBL3423810 | 0.86 | RHEB (0.52) | PIN1HRH4HRH3EGLN1RHEB | |
| SCHEMBL17092653 | 0.86 | EGLN1 (0.55) | PIN1HRH4HRH3EGLN1RHEB | |
| SCHEMBL5510194 | 0.80 | HRH4 (0.51) | PIN1HRH4HRH3EGLN1RHEB | |
| SCHEMBL2243699 | 0.79 | PIN1 (0.53) | PIN1HRH4HRH3EGLN1RHEB | |
| SCHEMBL2243706 | 0.79 | PIN1 (0.66) | PIN1HRH4HRH3EGLN1KDM4E | |
| SCHEMBL4309662 | 0.78 | EGLN1 (0.63) | PIN1EGLN1RHEBGRIN2DGRIN3B | |
| SCHEMBL11217318 | 0.78 | PIN1 (0.65) | PIN1EGLN1RHEBKDM4EHSD17B10 | |
| SCHEMBL11353502 | 0.77 | GRIN2D (0.67) | EGLN1KDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL20494985 | 0.76 | PIN1 (0.50) | PIN1HRH4EGLN1RHEBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504426-B2 | Heterocyclic compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-17 | — | — | US | claimed |
| EP-1545532-A2 | HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-29 | — | — | EP | claimed |
| US-20040058934-A1 | Heterocyclic compounds | JANSSEN PHARMACEUTIC, N.V. (BE) | 2004-03-25 | — | — | US | claimed |
| WO-2004022060-A2 | (1H-BENZOIMIDAZOL-2-YL)-(PIPERAZINYL)-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-03-18 | — | — | WO | claimed |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-09-21 | — | — | US | disclosed |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-09-21 | — | — | US | disclosed |
| EP-4161916-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2023-04-12 | — | — | EP | disclosed |
| US-10195195-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-02-05 | — | — | US | disclosed |
| EP-3378476-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | Sensorion (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-9688989-B2 | H4 receptor inhibitors for treating tinnitus | SENSORION (FR) | 2017-06-27 | — | — | US | disclosed |
| US-20170056397-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-03-02 | — | — | US | disclosed |
| EP-3130376-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-02-15 | — | — | EP | disclosed |
| WO-2010072829-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-07-01 | — | — | WO | disclosed |
| EP-2201982-A1 | Histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-06-30 | — | — | EP | disclosed |
| US-7504426-B2 | Heterocyclic compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-17 | — | — | US | disclosed |
| US-20090069343-A1 | Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus | DUNFORD PAUL J | 2009-03-12 | — | — | US | disclosed |
| US-20060111416-A1 | Octahydropyrrolo[3,4-C]pyrrole derivatives | PFIZER INC. | 2006-05-25 | — | — | US | disclosed |
| EP-1545532-A2 | HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-29 | — | — | EP | disclosed |
| US-20040058934-A1 | Heterocyclic compounds | JANSSEN PHARMACEUTIC, N.V. (BE) | 2004-03-25 | — | — | US | disclosed |
| WO-2004022060-A2 | (1H-BENZOIMIDAZOL-2-YL)-(PIPERAZINYL)-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111416-A1 | Octahydropyrrolo[3,4-C]pyrrole derivatives | DPYD, PAH, DHPS | PIN1 273/4885HRH4 1986/4885HRH3 3821/4885 |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | HCCS, HAVCR2, HDGF | PIN1 715/4885HRH4 1673/4885HRH3 987/4885 |
| US-20040058934-A1 | Heterocyclic compounds | HRH4, HRH2, HRH1 | PIN1 3002/4885HRH4 1/4885HRH3 4/4885 |
| US-20090069343-A1 | Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus | HRH4, HRH2, HRH3 | PIN1 831/4885HRH4 1/4885HRH3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.